Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus reuteri

What does the research say about Lactobacillus reuteri?

6 health outcomes synthesised

Research on Lactobacillus reuteri spans 6 health outcomes, primarily in oral health. The strongest evidence, from 5 studies, shows moderate support for reducing bleeding on probing (BOP) and improving clinical attachment in periodontitis patients. No consistent effective dose has emerged across trials, and many studies involved small samples, limiting generalizability.

Strongest evidence Three outcomes carry moderate evidence strength. For reduced bleeding on probing (BOP), 3 of 5 studies found benefit, but effects were mixed and two recent RCTs showed no benefit over placebo. For improved clinical attachment, 3 of 5 studies showed moderate beneficial effects, though one study in diabetic patients reported harm. For reduced probing pocket depth, 2 of 3 studies found moderate-to-large effects, but a high-quality RCT found no significant difference. No consistent dose or form was identified across any of these outcomes; lozenges were common but CFU varied.

Mixed or weaker evidence Three outcomes have low evidence strength. For reduced plaque index, 3 of 4 studies reported benefit, but the highest-quality RCT found no effect. For reduced gingival index, all 3 studies showed benefit with large effects, but the evidence base is small and at risk of publication bias. For reduced probing depth, only 1 of 3 RCTs showed benefit; the other two were neutral, suggesting possible population- or duration-dependent effects.

Effective dose patterns No cross-cutting effective dose range emerged. Only one study specified a dose (1×10⁹ CFU/day for 8 weeks) for probing depth reduction. Most trials did not consistently report CFU content, making dose-response assessment impossible.

Population insights Almost all studies focused on adults with periodontitis (stages III/IV), often including those with diabetes, betel quid chewing habits, or peri-implantitis. One study suggested potential harm in diabetic patients for clinical attachment, while another reported benefit in non-diabetics over 8 weeks but not in diabetics over 6 months for probing depth.

Notable caveats Several syntheses flagged possible publication bias, small sample sizes (20–30 per group in key RCTs), and inconsistent findings over time (recent trials show less benefit). One high-quality RCT per outcome often contradicted smaller positive studies. Doses and strains were poorly reported, limiting cross-study comparisons. A single study reported worsened clinical attachment in a diabetic subgroup.

Frequently asked

  • What is Lactobacillus reuteri good for according to research?
    Research has studied L. reuteri primarily for oral health outcomes in periodontitis patients. Moderate evidence from 5 studies suggests it may help reduce bleeding on probing and improve clinical attachment, though results are mixed. Weaker evidence indicates possible benefits for plaque index and gingival index, but high-quality studies often show no effect.
  • What dose of Lactobacillus reuteri is typically used in studies?
    No consistent effective dose has emerged across studies. Most trials did not report CFU content consistently; one study used 1×10⁹ CFU/day for 8 weeks. Lozenges were a common form, but specific doses varied widely, making it impossible to identify a standard regimen.
  • Who benefits most from Lactobacillus reuteri?
    The populations studied are mainly adults with periodontitis (stages III/IV), including those with diabetes or betel quid chewing habits. Some evidence suggests benefits may be more consistent in non-diabetic patients and over shorter durations (8–12 weeks), but findings are too limited to draw firm conclusions.
  • Are there caveats or limitations in the research on Lactobacillus reuteri?
    Yes. Several caveats were noted across syntheses: small sample sizes (20–30 per group), possible publication bias (recent RCTs show less benefit), and inconsistent quality. One high-quality RCT per outcome often found no significant effect, and doses/strains were poorly reported. One study even reported harm (worsened clinical attachment) in diabetic patients.
  • Does Lactobacillus reuteri help with bleeding on probing?
    Moderate evidence from 5 studies, with 3 reporting benefit and 2 finding no benefit over placebo. However, two recent RCTs (2024, 2025) found no additional benefit, suggesting possible publication bias or diminishing effect. Effects ranged from small to large, and overall clinical significance remains uncertain.
  • Does Lactobacillus reuteri improve clinical attachment in periodontitis?
    Moderate evidence from 5 studies: 3 reported moderate beneficial effects, 1 was neutral, and 1 reported a harmful effect in diabetic patients. Improvements were seen over 8–12 weeks to 6 months, but the evidence is tempered by small trials and one concerning finding of harm in a specific subgroup.

Most-studied combinations with Lactobacillus reuteri

most supplement research is combination research
Also studied with:Lactobacillus reuteri ATCC PTA 5289 (2)
Back to top